Gentian Diagnostics: Second quarter 2025 report

10 Jul 2025 08:00 CEST

Moss, 10 July 2025

Gentian Diagnostics ASA, a fast-growing developer and manufacturer of diagnostic
tests, today announced its results for the second quarter and first half year of
2025.

Highlights include:

Sales of NOK 43.6 million in 2Q25, up 14% vs 2Q24 (14% organic growth). Revenue
of NOK 88.1 million in 1H25 up 15% vs 1H24 (13% organic growth).

Sales of Cystatin C increased with 31% in 2Q25 compared to 2Q24. Strong increase
in sales to China indicates a return towards a normalised supply situation.

Continued US sales growth of 156% in 2Q25, and 94% in 1H25 with additional new
accounts established for Cystatin C and cCRP across several market segments.

EBITDA of NOK 1.7 million in 2Q25 versus NOK 6.8 million in 2Q24. EBITDA of NOK
15.7 million in 1H25 versus NOK 11.6 million in 1H24.

Production issues related to raw materials resulted in a gross margin of 44%,
down from 57% in 2Q24. Gross margin for 1H25 of 54%, versus 55% in 1H24.

Webcast
The company will present the results today at 09.00 am, followed by a Q&A
session. The presentation will be held as a live webcast on the company's
website:

https://www.gentian.com/investor-relation/presentations

The webcast will also be available on the company website after the
presentation.

IR contact:
Njaal Kind, CFO
njaal.kind@gentian.no
+47 919 06 525 (mobile)

This information is considered to be inside information pursuant to the EU
Market Abuse Regulation and is subject to the disclosure requirements pursuant
to Section 5-12 in the Norwegian Securities Trading Act.
This stock exchange announcement was published by Njaal Kind, CFO at Gentian
Diagnostics ASA, on 10 July 2025 at 08:00 CEST.


About Gentian
Gentian Diagnostics (OSE: GENT), develops and manufactures high-quality, in
vitro diagnostic reagents. Gentian’s expertise and focus lies within
immunoassays, specifically for infections, inflammation, kidney failure and
congestive heart failure. By converting existing and clinically relevant
biomarkers to the most efficient automated, high-throughput analysers, the
company contributes to saving costs and protecting life. Gentian Diagnostics is
headquartered in Moss, Norway, serving the global human and veterinary
diagnostics markets through sales and representative offices in Sweden, USA, and
China. For more information, please visit www.gentian.com.

More information:
Access the news on Oslo Bors NewsWeb site

650990_GDASA Q2 25 presentation.pdf
650990_GDASA Interim report 2Q 2025.pdf